Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
D 4.66 0.22% 0.01
VNDA closed up 0.22 percent on Friday, November 1, 2024, on 64 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Nov 6
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Crossed Above 20 DMA Bullish 0.22%
Gapped Up Strength 0.22%
Death Cross Bearish 2.19%
Fell Below 20 DMA Bearish 2.19%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Possible Inside Day about 17 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Fell Below 20 DMA about 18 hours ago
10 DMA Resistance about 18 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vanda Pharmaceuticals Inc. Description

Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Alcohol Clinical Development Oncology Organic Compounds Chemical Compounds Chemotherapy Schizophrenia Depression Central Nervous System Disorders Major Depressive Disorder Nervous System Disorders Depressive Disorder Sleep Disorders Pyridines Insomnia Nausea Treatment Of Major Depressive Disorder Sedatives Treatment Of Schizophrenia Treatment Of Central Nervous System Disorders Pruritus Chemotherapy Induced Nausea Fanapt Iloperidone

Is VNDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.75
52 Week Low 3.295
Average Volume 564,075
200-Day Moving Average 4.88
50-Day Moving Average 4.83
20-Day Moving Average 4.65
10-Day Moving Average 4.66
Average True Range 0.19
RSI (14) 47.92
ADX 19.17
+DI 26.02
-DI 19.88
Chandelier Exit (Long, 3 ATRs) 4.74
Chandelier Exit (Short, 3 ATRs) 4.91
Upper Bollinger Bands 4.95
Lower Bollinger Band 4.36
Percent B (%b) 0.51
BandWidth 12.69
MACD Line -0.04
MACD Signal Line -0.05
MACD Histogram 0.0102
Fundamentals Value
Market Cap 268.12 Million
Num Shares 57.5 Million
EPS 0.04
Price-to-Earnings (P/E) Ratio 116.50
Price-to-Sales 1.24
Price-to-Book 0.44
PEG Ratio -2.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.80
Resistance 3 (R3) 4.80 4.75 4.77
Resistance 2 (R2) 4.75 4.72 4.75 4.76
Resistance 1 (R1) 4.71 4.70 4.71 4.71 4.76
Pivot Point 4.66 4.66 4.66 4.66 4.66
Support 1 (S1) 4.62 4.63 4.62 4.62 4.56
Support 2 (S2) 4.57 4.61 4.57 4.56
Support 3 (S3) 4.53 4.57 4.55
Support 4 (S4) 4.53